Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.

Revenue projections:

Revenue projections for ABBOTINDIA
Revenue projections for ABBOTINDIA

ABBOTINDIA is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 2.554000
forwardPE 28.224247
debtToEquity 3.602000
earningsGrowth 0.076000
revenueGrowth 0.065000
grossMargins 0.467050
operatingMargins 0.270120
trailingEps 729.170000
forwardEps 908.793100

ABBOTINDIA's current ratio 2.554, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, ABBOTINDIA can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
Abbott India Limited's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
Abbott India Limited's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
ABBOTINDIA's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that ABBOTINDIA's financial performance will improve in the current financial year.

Price projections:

Price projections for ABBOTINDIA
Price projections for ABBOTINDIA

The current price of ABBOTINDIA aligns with projections, showing no clear risks or opportunities. This lack of volatility suggests a stable environment for investors, who may wish to hold off on major adjustments until market conditions change.

Recommendation changes over time:

Recommendations trend for ABBOTINDIA
Recommendations trend for ABBOTINDIA


The analysts' recent buy bias for ABBOTINDIA indicates strong confidence in the stock's future performance. This could encourage more investors to view ABBOTINDIA as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.